Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Steep Share Price Declines And DCF Outlook

Simply Wall St.02-09 07:12

If you are wondering whether Recursion Pharmaceuticals' current share price lines up with its underlying worth, you are not alone. This article will walk through what the numbers suggest about value. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610073505?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-02-09 07:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610073505","market":"nz","top_or_hot":-1,"title":"Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Steep Share Price Declines And DCF Outlook","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Recursion Pharmaceuticals' current share price lines up with its underlying worth, you are not alone. This article will walk through what the numbers suggest about value. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/is-recursion-pharmaceuticals-rxrx-pricing-reflect-its-steep\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Steep Share Price Declines And DCF Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Recursion Pharmaceuticals (RXRX) Pricing Reflect Its Steep Share Price Declines And DCF Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-09 07:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/is-recursion-pharmaceuticals-rxrx-pricing-reflect-its-steep><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Recursion Pharmaceuticals' current share price lines up with its underlying worth, you are not alone. This article will walk through what the numbers suggest about value. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/is-recursion-pharmaceuticals-rxrx-pricing-reflect-its-steep\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4609","symbol_name":"英伟达持仓股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/is-recursion-pharmaceuticals-rxrx-pricing-reflect-its-steep","article_id":"2610073505","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rxrx/recursion-pharmaceuticals/news/is-recursion-pharmaceuticals-rxrx-pricing-reflect-its-steep","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2610073505","pubTimestamp":1770592335,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Recursion Pharmaceuticals' current share price lines up with its underlying worth, you are not alone. This article will walk through what the numbers suggest about value.\nThe stock last closed at US$3.98, after share price returns of a 5.0% decline over 7 days, 14.6% decline over 30 days, 5.2% decline year to date, and 46.9% decline over the past year, with a 51.4% decline over three years.\nRecently, headlines around Recursion Pharmaceuticals have focused on its...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4609":"英伟达持仓股","BK4539":"次新股","BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4611":"AI医疗","RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"Recursion Pharmaceuticals(RXRX)的定价是否反映了其股价大幅下跌和DCF前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1.98},"content_text":"If you are wondering whether Recursion Pharmaceuticals' current share price lines up with its underlying worth, you are not alone. This article will walk through what the numbers suggest about value. The stock last closed at US$3.98, after share price returns of a 5.0% decline over 7 days, 14.6% decline over 30 days, 5.2% decline year to date, and 46.9% decline over the past year, with a 51.4% decline over three years. Recently, headlines around Recursion Pharmaceuticals have focused on its position as a drug discovery company using technology and data driven approaches. This has kept investor attention on how its long term projects might translate into value. This context helps frame the recent share price moves as the market digests both the potential and the risks tied to its pipeline and business model. On our checks, Recursion Pharmaceuticals scores 2 out of 6 on valuation, as outlined in our valuation summary. Next we will compare what different valuation approaches say about that score, then finish with a way of looking at valuation that can give you a fuller picture than any single metric.  Recursion Pharmaceuticals scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Recursion Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model estimates what a business could be worth by projecting its future cash flows and then discounting those back to today using a required rate of return. For Recursion Pharmaceuticals, the 2 Stage Free Cash Flow to Equity model starts from last twelve months free cash flow of about $453.7 million in outflows, so the business is currently burning cash. Analyst and extrapolated estimates then move through a period where cash flows stay negative in the near term, with projections such as $17.5 million and $86 million in outflows in 2026 and 2027, before shifting to positive free cash flow. By 2030, free cash flow is projected at $176 million, with further positive figures through 2035 based on Simply Wall St extrapolations. Discounting this stream of projected cash flows back to today gives an estimated intrinsic value of about $9.62 per share. Compared with the recent share price of US$3.98, this model implies the stock is about 58.6% undervalued on these assumptions. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Recursion Pharmaceuticals is undervalued by 58.6%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks. RXRX Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Recursion Pharmaceuticals. Approach 2: Recursion Pharmaceuticals Price vs Sales For companies where profits are limited or volatile, the P/S ratio is often more useful than P/E because it compares the market value of the business with the revenue it generates, without relying on positive earnings. What investors usually look for with P/S is how the market is weighing growth potential and risk. Higher growth or lower perceived risk can support a higher multiple, while slower growth or higher uncertainty tends to point to a lower, more conservative range. Recursion Pharmaceuticals currently trades on a P/S of about 47.41x. That is well above the Biotechs industry average P/S of about 11.15x and the peer group average of about 9.80x. Simply Wall St also calculates a proprietary “Fair Ratio” for each company. This is the P/S multiple it might typically trade on given factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it blends these fundamentals into one number, the Fair Ratio can give you a more tailored anchor than a simple comparison with sector or peer averages. Result: OVERVALUED NasdaqGS:RXRX P/S Ratio as at Feb 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies. Upgrade Your Decision Making: Choose your Recursion Pharmaceuticals Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, a simple way for you to spell out the story behind your numbers, including your assumed fair value and your estimates for future revenue, earnings and margins. A Narrative links what you believe about a company, such as Recursion Pharmaceuticals progress with its technology and drug discovery efforts, to a set of forecasts and then to a fair value that you can compare directly with today’s share price. On Simply Wall St, Narratives sit inside the Community page, where millions of investors can use this tool to quickly see how their view of Recursion Pharmaceuticals translates into a Fair Value vs Price comparison. This can help them decide whether it might be a time to buy, hold or sell according to their own criteria. Narratives also update automatically when new information such as earnings or major news arrives. You can see, for example, one Recursion Pharmaceuticals Narrative with a very optimistic fair value and strong long term assumptions sitting alongside another that is much more conservative on future cash flows and margins. Do you think there's more to the story for Recursion Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGS:RXRX 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610073505","isCrawlerRequest":true}